The selection of appropriate chemotherapeutic and/or radiation therapy for small cell lung cancer should be done after careful diagnosis and staging workup. A patient with small cell lung cancer is presented and explanation given for each step in diagnosis and staging.
(CHEST 1995; 107:241S-242S) Small cell lung cancer (SCLC) accounts for only 15 to 20% of all lung cancer cases. However, the unique sensitivity of this cell type to chemotherapy and radiation therapy has led to the classification of the five or more cell types of lung cancer into the two categories of SCLC and non-small cell lung cancer (NSCLC) . NSCLC where consideration of a multimodality approach would be more appropriate than surgical resection alone. If, as the scenario suggests, the patient has SCLC, then lobectomy might confirm the diagnosis, but without any potential therapeutic benefit as the treatment is usually nonsurgical.
Fiberoptic bronchoscopy would provide the highest possible diagnostic yield for both SCLC and NSCLC. Because the chest radiograph indicates the presence of an obstructing endobronchial lesion, the expected yield of an endobronchial examination with washings and brushings obtained for cytologic studies and endobronchial biopsy specimens for histopathologic examination would be very high, with low concomitant morbidity (cough during the procedure, minor risk of bleeding, or pneumothorax). In the event of NSCLC, bronchoscopy allows preoperative endobronchial staging of the extent of tumor in the tracheobronchial tree to help determine whether the lesion spares the tracheal carina and at least 2 cm of the mainstem bronchus, and is therefore still resectable. Commonly, lung cancer is but one of several possibilities on the list of differential diagnoses. Fiberoptic bronchoscopy would also expedite verification of TB, sarcoidosis, and other nonneoplastic disorders, as well as the exclusion of a synchronous primary.
In this case, fiberoptic bronchoscopy revealed an obstructing lesion in the anterior segment of the right upper lobe. Endobronchial biopsy specimens and bronchial washings were diagnostic of SCLC.
STAGING WORKUP
To allow tailored treatment, SCLC must be classified as either limited disease, generally defined as disease confined to a single hemithorax, mediastinum, and/or ipsilateral supraclavicular lymph nodes, or extensive disease, having spread beyond those regions and no longer able to be encompassed within a single radiotherapy portal.5 The most common sites of metastatic spread for SCLC are outlined in Table  1 . To detect these local and distant sites of spread, the staging workup might logically include the patient's medical history and results of physical examination, complete blood cell count, serum chemistry studies and liver function tests (ALT, AST, alkaline phosphatase, bilirubin, and LDH), chest radiograph, chest 
